TABLE 3.
Description of effective antimicrobial therapy and definitive antimicrobial therapy in the presence and in the absence of Verigene results
| Parameter | Valuea
in the case that Verigene results were: |
P value | |
|---|---|---|---|
| Available (n = 52) | Absent (n = 9) | ||
| Pathogen group | <0.001 | ||
| ESBL-E | 26 (42.6) | 0 | |
| CRE | 8 (15.4) | 7 (46.7) | |
| Nonfermenters | 18 (32.8) | 2 (22.2) | |
| Management | |||
| Median days of inpatient treatment (IQR) | 7.4 (5.5, 14.1) | 7.8 (5, 13.4) | 0.87 |
| Patients who received effective treatment | 51 (98.1) | 9 (100) | 1 |
| Patients with potential improved time to effective treatment | 18 (34.6) | 6 (75) | 0.14 |
| Time (h) from blood draw to effective treatment,b median (IQR) | 23.6 (14.9, 37.4) | 57.8 (41.5, 78.6) | 0.002 |
| Time (h) from positive culture to effective treatment,b median (IQR) | 6.1 (0, 19.2) | 42.7 (28.5, 50.4) | <0.001 |
| Potential improvement (h) from blood draw to effective treatment,c median (IQR) | 12.6 (3.7, 21.7) | 30.8 (19.7, 49.1) | 0.01 |
| Patients who received definitive treatment | 52 (100) | 9 (100) | 1 |
| Patients with potential improved time to definitive treatment | 22 (42.3) | 6 (66.7) | 0.28 |
| Time from blood draw to definitive treatment,d median (IQR) | 40.2 (24.1, 77.7) | 78.6 (57.8, 86.7) | 0.04 |
| Time (h) from positive culture to definitive treatment,d median (IQR) | 22.3 (6.2, 62.4) | 50.4 (42.7, 129.3) | 0.05 |
| Potential improvement (h) from blood draw to definitive treatment,e median (IQR) | 26.7 (11.6, 39.3) | 42 (26.4, 49.1) | 0.07 |
Unless otherwise noted, data are presented as number (percent).
Evaluated among patients who received effective therapy in each group: n = 51 for the group with Verigene results available and n = 9 for the group for which Verigene results were absent.
Evaluated among patients who had potential benefit to reduce time to effective therapy by using Accelerate system’s results, compared to traditional culture results in each group: n = 18 for the group with Verigene results available and n = 6 for the group for which Verigene results were absent.
Evaluated among patients who received definitive therapy in each group, n = 52 for the group with Verigene results available and n = 9 for the group for which Verigene results were absent.
Evaluated among patients who had potential benefit to reduce time to definitive therapy by using Accelerate system’s results, compared to traditional culture results in each group, n = 22 for the group with Verigene results available and n = 6 for the group for which Verigene results were absent.